N/A
N=28
Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
Benign Prostatic Hyperplasia (BPH)
Bottom Line
View on ClinicalTrials.gov: NCT03052049 ↗Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Apr 2023
Primary outcome: Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Prostate Artery Embolization (Device)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- Male
- Sponsor
- Northwestern University
- Primary completion
- Sep 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . |
6; 10; 0; 0; 0 | 0.05 |
| SECONDARY Change in International Prostate Symptom Score (IPSS) |
25; 13; 8; 7; 9 | 0.05 |
| SECONDARY Change in Quality of Life (QOL) Bother Score |
5; 2; 1; 1; 1 | 0.05 |
| SECONDARY Change in Benign Prostatic Hyperplasia (BPH) Impact Index Score |
9; 3.5; 2.5; 2.3; 2.1 | 0.05 |
| SECONDARY Change in Peak Urine Flow (Qmax) |
5.9; 9.9; 13.2; 7; 9.1 | 0.05 |
Summary
This is an open-labeled, non-randomized feasibility study to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH).
Eligibility Criteria
Inclusion Criteria
- Diagnosis of LUTS secondary to BPH refractory to/contraindicated for medical treatment. Patients with indwelling foley catheters will be treated with culture directed antibiotics one time for 5-7 days. The catheter will be removed so urodynamic testing and cystoscopy can be completed as part of the screening visit. It will be replaced when testing is completed.
- Ability to understand and the willingness to sign a written informed consent.
- Prostate volumes 40 - 200 gm. May include 30-39 gm if the subject has a long history of ineffective response to combination medical treatments (alpha-blocker and a 5-alpha reductase inhibitor) for at least 6 months.
- Men ≥ 45 years of age
- IPSS symptom score ≥ 18 and IPSS bother score ≥ 3
- Peak flow rate Qmax≤ 12 with voided volume ≥125 cc
- For men 45-59 years old: Prostate Specific Antigen) PSA 60: PSA 6 months prior are eligible)
- renal insufficiency (i.e. creatinine > 1.8)
- Known primary neurologic conditions such as multiple sclerosis or Parkinson's disease or other neurological diseases known to affect bladder function.
- Neurogenic bladder, Hypotonic Bladder
- Prior treatment for urinary incontinence
- Penile prosthesis.
- Artificial urinary sphincter.
- Documented bacterial prostatitis within the past year.
- Active urinary tract infection (UTI) unless in case of regular catheter dependence and thought to represent colonization.
- History of chronic prostatitis within the last 1 year
- Known bleeding disorders (e.g. VWD)
- Prior prostate procedures (e.g. Transurethral Microwave Therapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Water-induced Thermotherapy (WIT), Transurethral Resection of the Prostate (TURP), Photoselective Vaporization of the Prostate (PVP)
- Prior treatment for overactive bladder (e.g. intravesical botox)
- Enrolled in another treatment trial for any disease within the past 30 days
- Declines or unable to provide informed consent
- Condition precluding catheter-based intervention (ie occluded vessel, severe atheromatous disease)
- Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, uncontrolled diabetes, cardiac arrhythmias, cardiac disease including congestive heart failure, significant respiratory disease, or known immunosuppression.
- A history of rectal malignancy
- Prior surgical prostate intervention
- Interest in future fertility
- Allergy to iodinated contrast agents not responsive to steroid premedication regimen
- Contraindication to conscious sedation
Data sourced from ClinicalTrials.gov (NCT03052049). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.